Singapore-based biotech startup Anomaly Bio has raised $2.6 million in pre-seed funding led by the United States-based Pebblebed Ventures.
The firm said in a statement on Wednesday that the round also saw participation from Akshay Kothari (Notion), Sean Hunt (Solugen), Eben Bayer (Ecovative), and Mithun Sacheti (CaratLane).
The new funding will enable Anomaly Bio to set up its own laboratory and pilot-scale facilities in Singapore, alongside expanding its research and development (R&D) team in metabolic engineering.
“As the world’s ingredient landscape transforms, we want to build a global ingredients company from the ground up,
“There is a rare opportunity to stand alongside legacy industry leaders, but powered by synthetic biology and advanced fermentation,” said its Founder Armaan.
It is noted around the world, ingredient supply chains are cracking under pressure from geopolitical and environmental shocks.
Tariffs, wars, pandemics, and droughts have turned once-reliable systems into an unpredictable patchwork of delays and shortages that threaten everyday essentials.
From vanilla crops in Madagascar destroyed by cyclones to fertilizer and grain shortages triggered by the Russia–Ukraine war, disruptions have rippled through global markets, driving record price volatility in commodities such as cocoa, palm oil, corn, and sugarcane.
These are not isolated events, but symptoms of a deeper structural fragility in the global supply system.
Anomaly’s solution turns microbes into micro-factories that replace fragile supply chains with a new form of manufacturing that is scalable, on demand, and viable anywhere in the world.
By engineering microbes to convert sugar into bio-based ingredients, Anomaly aims to unlock new possibilities within crop protection, nutrition, personal care and beyond.
It is also noted that the global economic order is under strain.
As Singapore Deputy Prime Minster Gan Kim Yong recently highlighted, rising protectionism and the fragmentation of global trade threaten the very interdependence that once powered global prosperity.
His call for “flexible multilateralism” underscores Singapore’s vision of a rules-based yet resilient global economy.
Anomaly Bio views its work as part of Singapore’s broader push to strengthen advanced manufacturing.
Through on-demand and scalable ingredient production powered by biotechnology, the company aims to help build sustainable and reliable manufacturing capabilities that enhance, not replace, global trade networks.
“With a government that’s proactively supporting advanced biomanufacturing, we believe that Singapore is the right ecosystem to build a truly global bio-ingredient company,” said Samyak, Anomaly Bio’s Co-founder.
Anomaly Bio is a Singapore-based company that develops next-generation bio-based inputs through advanced fermentation and strain engineering.
Before this fundraise, the firm received over $120,000 in non-dilutive awards from MIT’s WFA Prize 2025 and the WTFund Fellowship, alongside support from NUS and Mars Petcare’s Next Generation Pet Food Program.
Singapore-based biotechnology company Terra Oleo raises $3.1M funding